Treatment Cohort | Notes of clarification | Outcome #cured/total (%) |
---|---|---|
TQ Alone* | ||
Cohort 3 | TQ given alone after quinine pretreatment | 6/6 (100) |
TQ + CQ 16 | ||
Cohort 1** | CQ given sequentially after blood stage failure of first tafenoquine treatment regimen | 2/2 (100) |
Cohort 2 | CQ + TQ given simultaneously for first treatment | 2/2 (100) |
TQ + CQ 24 | ||
Cohort 1 | CQ given sequentially after blood stage failure of first relapse treatment | 2/2 (100) |
Cohort 1 | Treatment of second relapse | 1/2 (50) |
Cohort 2 | CQ + TQ given simultaneously for first treatment | 5/5 (100) |
Cohort 3 | TQ given with CQ after quinine pretreatment to eliminate blood stage parasites | 6/6 (100) |
Unpublished data | TQ given as a single dose for first treatment (data not shown) | 2/2 (100) |
TQ + Other Anti-malarials | ||
Cohort 2 | Simultaneous combination with artemether-lumefantrine for initial treatment | 5/6 (83) |
Unpublished data | Simultaneous combination with atovaquone-proguanil for initial treatment (data not shown) | 2/2 (100) |
Total | ||
Tafenoquine alone | 6/6 (100) | |
TQ + CQ | 20/21 (95) | |
TQ + all BS**All | 27/29 (93) | |
TQ | 33/35 (94) |